British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector.

Luke Miels will take over on January 1 from Walmsley, who will have been at the helm for almost nine years, GSK said in an unexpected announcement.

GSK earlier this month said it planned to invest $30 billion in the United States over the next five years.

The investment was announced before US President Donald Trump said last week that he would impose 100-percent tariffs on all branded pharmaceutical products from Wednesday, unless companies are building manufacturing plants in the United States.

"2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the righ

See Full Page